{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:26:07Z","timestamp":1782512767096,"version":"3.54.5"},"reference-count":78,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anticoagulants have been in use for nearly a century for the treatment and prevention of venous and arterial thromboembolic disorders. The most dreaded complication of anticoagulant treatment is the occurrence of bleeding, which may be serious and even life-threatening. All available anticoagulants, which target either multiple coagulation factors or individual components of the tissue factor (TF) factor VIIa or the common pathways, have the potential to affect hemostasis and thus to increase bleeding risk in treated patients. While direct oral anticoagulants introduced an improvement in care for eligible patients in terms of safety, efficacy, and convenience of treatment, there remain unmet clinical needs for patients requiring anticoagulant drugs. Anticoagulant therapy is sometimes avoided for fear of hemorrhagic complications, and other patients are undertreated due to comorbidities and the perception of increased bleeding risk.<\/jats:p><jats:p>Evidence suggests that the contact pathway of coagulation has a limited role in initiating physiologic in vivo coagulation and that it contributes to thrombosis more than it does to hemostasis. Because inhibition of the contact pathway is less likely to promote bleeding, it is an attractive target for the development of anticoagulants with improved safety.<\/jats:p><jats:p>Preclinical and early clinical data indicate that novel agents that selectively target factor XI or factor XII can reduce venous and arterial thrombosis without an increase in bleeding complications.<\/jats:p>","DOI":"10.1182\/hematology.2022000386","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:12:45Z","timestamp":1670602365000},"page":"495-505","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism"],"prefix":"10.1182","volume":"2022","author":[{"given":"Omri","family":"Cohen","sequence":"first","affiliation":[{"name":"1 National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel"},{"name":"2 Sackler School of Medicine, Tel\u2009Aviv University, Israel"},{"name":"3 Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"3 Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"1","key":"2022121313293545600_hem2022000386C1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2022121313293545600_hem2022000386C2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.chest.2017.03.048","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia","volume":"152","author":"Bai","year":"2017","journal-title":"Chest"},{"issue":"5","key":"2022121313293545600_hem2022000386C3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022121313293545600_hem2022000386C4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2022121313293545600_hem2022000386C5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOH.0b013e3283497e61","article-title":"Factor XI and XII as antithrombotic targets","volume":"18","author":"M\u00fcller","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2022121313293545600_hem2022000386C6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2022121313293545600_hem2022000386C7","first-page":"261","article-title":"Laboratory monitoring of low-molecular-weight heparin and fondaparinux","volume":"43","author":"Babin","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"2022121313293545600_hem2022000386C8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"International Warfarin Pharmacogenetics Consortium","year":"2009","journal-title":"N Engl J Med"},{"issue":"6, suppl","key":"2022121313293545600_hem2022000386C9","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"3","key":"2022121313293545600_hem2022000386C10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0036-1597297","article-title":"Laboratory monitoring of parenteral direct thrombin inhibitors","volume":"43","author":"Van Cott","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"2022121313293545600_hem2022000386C11","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"9921","key":"2022121313293545600_hem2022000386C12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"2022121313293545600_hem2022000386C13","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2022121313293545600_hem2022000386C14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0040-1701476","article-title":"Oral anticoagulation in the elderly and frail","volume":"40","author":"Bauersachs","year":"2020","journal-title":"Hamostaseologie"},{"issue":"1","key":"2022121313293545600_hem2022000386C15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/phar.2345","article-title":"Timing of initiation of oral anticoagulation after acute ischemic stroke in patients with atrial fibrillation","volume":"40","author":"Smythe","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2022121313293545600_hem2022000386C16","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","article-title":"Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study","volume":"46","author":"Paciaroni","year":"2015","journal-title":"Stroke"},{"issue":"1","key":"2022121313293545600_hem2022000386C17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/hematology.2020000151","article-title":"Combining antiplatelet and anticoagulant therapy in cardiovascular disease","volume":"2020","author":"Barnes","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2022121313293545600_hem2022000386C18","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2022121313293545600_hem2022000386C19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2022121313293545600_hem2022000386C20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"24","key":"2022121313293545600_hem2022000386C21","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2022121313293545600_hem2022000386C22","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jth.15364","article-title":"Treatment of bleeding in patients with liver disease","volume":"19","author":"Northup","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2022121313293545600_hem2022000386C23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/liv.14366","article-title":"What's new in portal hypertension?","volume":"40","author":"Mauro","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"2022121313293545600_hem2022000386C24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2022121313293545600_hem2022000386C25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2019.10.059","article-title":"Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis","volume":"75","author":"Kuno","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2022121313293545600_hem2022000386C26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1060028020967635","article-title":"Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes","volume":"55","author":"Cheung","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2022121313293545600_hem2022000386C27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jth.13235","article-title":"Contact system revisited: an interface between inflammation, coagulation, and innate immunity","volume":"14","author":"Long","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2022121313293545600_hem2022000386C28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/rth2.12217","article-title":"The contact pathway and sepsis","volume":"3","author":"Raghunathan","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2022121313293545600_hem2022000386C29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/asheducation-2014.1.60","article-title":"Recent insights into the role of the contact pathway in thrombo-inflammatory disorders","volume":"2014","author":"van Montfoort","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2022121313293545600_hem2022000386C30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2022121313293545600_hem2022000386C31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection","volume":"19","author":"Demoulin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2022121313293545600_hem2022000386C32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17474086.2016.1191944","article-title":"Why factor XI deficiency is a clinical concern","volume":"9","author":"Wheeler","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"2022121313293545600_hem2022000386C33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1055\/s-0041-1735971","article-title":"The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events","volume":"122","author":"Sharman Moser","year":"2022","journal-title":"Thromb Haemost"},{"issue":"3","key":"2022121313293545600_hem2022000386C34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.thromres.2009.11.028","article-title":"Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis","volume":"125","author":"Stavrou","year":"2010","journal-title":"Thromb Res"},{"issue":"1","key":"2022121313293545600_hem2022000386C35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10328","key":"2022121313293545600_hem2022000386C36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2022121313293545600_hem2022000386C37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12195-020-00657-6","article-title":"Development of coagulation factor XII antibodies for inhibiting vascular device-related thrombosis","volume":"14","author":"Kohs","year":"2021","journal-title":"Cell Mol Bioeng"},{"issue":"6","key":"2022121313293545600_hem2022000386C38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2022121313293545600_hem2022000386C39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"2022121313293545600_hem2022000386C40","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2022121313293545600_hem2022000386C41","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2022121313293545600_hem2022000386C42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"2022121313293545600_hem2022000386C43","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41598-017-02055-x","article-title":"Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa","volume":"7","author":"Donkor","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"2022121313293545600_hem2022000386C44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0035-1546466","article-title":"Next generation antithrombotic therapy: focus on antisense therapy against coagulation factor XI","volume":"41","author":"Lippi","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"2022121313293545600_hem2022000386C45","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2022121313293545600_hem2022000386C46","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/jth.15236","article-title":"Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"19","author":"Ngo","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2022121313293545600_hem2022000386C47","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2011-10-387134","article-title":"Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys","volume":"119","author":"Younis","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2022121313293545600_hem2022000386C48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"2022121313293545600_hem2022000386C49","article-title":"ISISFXI-Rx, a novel and specific antisense inhibitor of factor XI, caused a significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2022121313293545600_hem2022000386C50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"13","key":"2022121313293545600_hem2022000386C51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2022121313293545600_hem2022000386C52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2022121313293545600_hem2022000386C53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"2022121313293545600_hem2022000386C54","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"issue":"6","key":"2022121313293545600_hem2022000386C55","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/FJC.0000000000000921","article-title":"Osocimab: a novel agent in preventing venous thromboembolism","volume":"76","author":"Beavers","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"2022121313293545600_hem2022000386C56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2022121313293545600_hem2022000386C57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"2022121313293545600_hem2022000386C58","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17460441.2017.1384811","article-title":"Discovery methods of coagulation-inhibiting drugs","volume":"12","author":"G\u00f3mez-Outes","year":"2017","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"2022121313293545600_hem2022000386C59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/ATVBAHA.119.312459","article-title":"AB023, a novel antibody that binds factor XI and blocks its activation by factor XIIa","volume":"39","author":"Chan","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2022121313293545600_hem2022000386C60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"2022121313293545600_hem2022000386C61","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2022121313293545600_hem2022000386C62","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"issue":"2","key":"2022121313293545600_hem2022000386C63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2022121313293545600_hem2022000386C64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"6","key":"2022121313293545600_hem2022000386C65","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40262-022-01110-9","article-title":"Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"2022121313293545600_hem2022000386C66","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2022121313293545600_hem2022000386C67","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"10333","key":"2022121313293545600_hem2022000386C68","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"2022121313293545600_hem2022000386C69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1753944710387808","article-title":"New parenteral anticoagulants in development","volume":"5","author":"G\u00f3mez-Outes","year":"2011","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"4","key":"2022121313293545600_hem2022000386C70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11239-015-1258-7","volume":"40","author":"Wong","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"25","key":"2022121313293545600_hem2022000386C71","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2013-08-517474","article-title":"Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo","volume":"122","author":"Ma","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2022121313293545600_hem2022000386C72","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.12797","article-title":"Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity","volume":"13","author":"Chen","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2022121313293545600_hem2022000386C73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.gene.2004.07.012","article-title":"A thrombin inhibitor from the ixodid tick, Amblyomma hebraeum","volume":"342","author":"Lai","year":"2004","journal-title":"Gene"},{"key":"2022121313293545600_hem2022000386C74","doi-asserted-by":"crossref","first-page":"112753","DOI":"10.1016\/j.ejmech.2020.112753","article-title":"Factor XII\/XIIa inhibitors: their discovery, development, and potential indications","volume":"208","author":"Davoine","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"17","key":"2022121313293545600_hem2022000386C75","first-page":"247","article-title":"The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann Transl Med"},{"issue":"3","key":"2022121313293545600_hem2022000386C76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cts.13192","article-title":"Pharmacokinetic\/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated factor XII inhibitor garadacimab (CSL312)","volume":"15","author":"Pawaskar","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"3","key":"2022121313293545600_hem2022000386C77","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cts.13180","article-title":"A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab","volume":"15","author":"McKenzie","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2022121313293545600_hem2022000386C78","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jth.15579","article-title":"A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors","volume":"20","author":"Salomon","year":"2022","journal-title":"J Thromb Haemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/495\/2023086\/495cohen.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/495\/2023086\/495cohen.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T19:14:38Z","timestamp":1701544478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/495\/493544\/Coming-soon-to-a-pharmacy-near-you-FXI-and-FXII"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000386","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}